AstraZeneca
Owkin, AstraZeneca Partner to Develop AI-Based Breast Cancer Prescreening Tool
The solution will use Owkin's data network and artificial intelligence to prescreen for gBRCA mutations in breast cancer directly from digital pathology slides.
Pillar Biosciences, AstraZeneca Partner on Liquid Biopsy Testing in Europe
AstraZeneca has partnered with several other firms on liquid biopsies, including Angle, Sophia Genetics, IMBdx, and Guardant Health.
Foundation Medicine Nets FDA Approval for Tissue, Liquid NGS CDx for Lynparza Combo
The FDA approved FoundationOne CDx and FoundationOne Liquid for identifying BRCA1/2-mutated mCRPC patients eligible for Lynparza, Zytiga, and a steroid.
Qiagen, AstraZeneca Expand CDx Collaboration Beyond Cancer
Under the agreement, Qiagen will develop and validate a genotyping assay using its QiaStat-Dx platform.
Io9 AI-Driven Digital Pathology Test Shows Potential to Inform Breast, Ovarian Cancer Therapy
Premium
The firm hopes to develop its DeepHRD digital pathology test as an alternative to costly companion diagnostics based on next-generation sequencing.
Jun 24, 2022
Almac, AstraZeneca Strike CDx Development Pact
Jun 22, 2022